bf/NASDAQ:RNAZ_icon.jpeg

NASDAQ:RNAZ

TransCode Therapeutics

  • Stock

USD

Last Close

9.29

06/11 21:04

Market Cap

5.96M

Beta: -

Volume Today

129.53M

Avg: 1.67M

PE Ratio

−0.06

PFCF: −0.23

OverviewFinancialsAPI

    Description

    TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based mo...Show More

    Excel Tearsheet

    Earnings

    Earnings per Share (Estimate*)

    -250-200-150-100-502019-12-302020-12-312022-03-312023-08-142024-06-172025-04-07

    Revenue (Estimate*)

    50K100K150K200K250K300K2019-12-302020-12-312022-03-312023-08-142024-06-172025-04-07

    *Estimate based on analyst consensus